Increased expression of dopamine receptors in synovial fibroblasts from patients with rheumatoid arthritis: Inhibitory effects of dopamine on interleukin-8 and interleukin-6

Arthritis and Rheumatology

Volumn 66, Issue 10, 2014, Pages 2685-2693

  Capellino, Silvia ^a,d   Cosentino, Marco ^b   Luini, Alessandra ^b   Bombelli, Raffaella ^b   Lowin, Torsten ^a   Cutolo, Maurizio ^c   Marino, Franca ^b   Straub, Rainer H ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b UNIVERSITY OF INSUBRIA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 O METHYLDOPAMINE; DIHYDROXYPHENYLACETIC ACID; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR; DOPAMINE RECEPTOR; DOPAMINE TRANSPORTER; HOMOVANILLIC ACID; INTERLEUKIN 6; INTERLEUKIN 8; LEVODOPA; MESSENGER RNA; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TYROSINE 3 MONOOXYGENASE;

ADULT; AGED; ARTICLE; CELL DENSITY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; FEMALE; FIBROBLAST; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; KNEE ARTHROPLASTY; MACROPHAGE; MALE; METABOLITE; OSTEOARTHRITIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; SYNOVIUM; CELL CULTURE; DRUG EFFECTS; METABOLISM;

ARTHRITIS, RHEUMATOID; CELLS, CULTURED; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FIBROBLASTS; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; MATRIX METALLOPROTEINASE 3; OSTEOARTHRITIS; RECEPTORS, DOPAMINE; SYNOVIAL MEMBRANE; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 84908388215     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38746     Document Type: Article

References (35)

1. Feldman RS, Meyer JS, Quenzer LF,. Catecholamines. In: Principles of neuropsychopharmacology. Sunderland (MA): Sinauer Associates; 1997. p. 277-344.
2. Basu S, Dasgupta PS,. Dopamine, a neurotransmitter, influences the immune system. J Neuroimmunol 2000; 102: 113-24.
3. Sarkar C, Basu B, Chakroborty D, Dasgupta PS, Basu S,. The immunoregulatory role of dopamine: an update. Brain Behav Immun 2010; 24: 525-8.
4. Levite M,. Dopamine in the immune system: dopamine receptors in immune cells, potent effects, endogenous production and involvement in immune and neuropsychiatric diseases. In:, Levite M, editor. Nerve-driven immunity: neurotransmitters and neuropeptides in the immune system. Vienna: Springer-Verlag; 2012. p. 1-45.
5. Cosentino M, Marino F,. Adrenergic and dopaminergic modulation of immunity in multiple sclerosis: teaching old drugs new tricks? J Neuroimmune Pharmacol 2013; 8: 163-79.
6. Beaulieu JM, Gainetdinov RR,. The physiology, signalling, and pharmacology of dopamine receptors. Pharmacol Rev 2011; 63: 182-217.
7. International Union of Basic and Clinical Pharmacology. IUPHAR database; dopamine receptors. 2012. URL: http://www.iuphar-db.org/DATABASE/FamilyMenuForward?familyId=20.
8. Marino F, Cosentino M, Bombelli R, Ferrari M, Lecchini S, Frigo G,. Endogenous catecholamine synthesis, metabolism storage, and uptake in human peripheral blood mononuclear cells. Exp Hematol 1999; 27: 489-95.
9. Cosentino M, Marino F, Bombelli R, Ferrari M, Lecchini S, Frigo G,. Endogenous catecholamine synthesis, metabolism, storage and uptake in human neutrophils. Life Sci 1999; 64: 975-81.
10. + regulatory T cells selectively express tyrosine hydroxylase and contain endogenous catecholamines subserving an autocrine/paracrine inhibitory functional loop. Blood 2007; 109: 632-42.
11. Sarkar C, Das S, Chakroborty D, Chowdhury UR, Basu B, Dasgupta PS, et al. Stimulation of dopamine D4 receptors induce T cell quiescence by up-regulating Kruppel-like factor-2 expression through inhibition of ERK1/ERK2 phosphorylation. J Immunol 2006; 177: 7525-9.
12. Pacheco R, Prado CE, Barrientos MJ, Bernales S,. Role of dopamine in the physiology of T-cells and dendritic cells. J Neuroimmunol 2009; 216: 8-19.
13. Laengle UW, Court M, Markstein R, Germann PG, Nogues V, Roman D,. Effects of anti-glaucoma drugs timolol and GLC756, a novel mixed dopamine D2 receptor agonist and D1 receptor antagonist, on endotoxin-induced-uveitis and -arthritis in rats. Exp Toxicol Pathol 2005; 57: 127-34.
14. Nakashioya H, Nakano K, Watanabe N, Miyasaka N, Matsushita S, Kohsaka H,. Therapeutic effect of D1-like dopamine receptor antagonist on collagen-induced arthritis of mice. Mod Rheumatol 2011; 21: 260-6.
15. Nakano K, Yamaoka K, Hanami K, Saito K, Sasaguri Y, Yanagihara N, et al. Dopamine induces IL-6-dependent IL-17 production via D1-like receptor on CD4 naive T cells and D1-like receptor antagonist SCH-23390 inhibits cartilage destruction in a human rheumatoid arthritis/SCID mouse chimera model. J Immunol 2011; 186: 3745-52.
16. Mukai E, Nagashima M, Hirano D, Yoshino S,. Comparative study of symptoms and neuroendocrine-immune network mediator levels between rheumatoid arthritis patients and healthy subjects. Clin Exp Rheumatol 2000; 18: 585-90.
17. Hirano D, Nagashima M, Ogawa R, Yoshino S,. Serum levels of interleukin 6 and stress related substances indicate mental stress condition in patients with rheumatoid arthritis. J Rheumatol 2001; 28: 490-5.
18. Erb N, Pace AV, Delamere JP, Kitas GD,. Control of unremitting rheumatoid arthritis by the prolactin antagonist cabergoline. Rheumatology (Oxford) 2001; 40: 237-9.
19. Eijsbouts A, van den Hoogen F, Laan RF, Hermus RM, Sweep FC, van de Putte L,. Treatment of rheumatoid arthritis with the dopamine agonist quinagolide. J Rheumatol 1999; 26: 2284-5.
20. Capellino S, Cosentino M, Wolff C, Schmidt M, Grifka J, Straub RH,. Catecholamine-producing cells in the synovial tissue during arthritis: modulation of sympathetic neurotransmitters as new therapeutic target. Ann Rheum Dis 2010; 69: 1853-60.
21. Jenei-Lanzl Z, Capellino S, Kees F, Fleck M, Lowin T, Straub RH,. Anti-inflammatory effects of cell-based therapy with tyrosine hydroxylase-positive catecholaminergic cells in experimental arthritis. Ann Rheum Dis 2013. E-pub ahead of print.
22. Huber LC, Distler O, Tarner I, Gay RE, Gay S, Pap T,. Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology (Oxford) 2006; 45: 669-75.
23. Filer A,. The fibroblast as a therapeutic target in rheumatoid arthritis. Curr Opin Pharmacol 2013; 13: 413-9.
24. Leech MT, Morand EF,. Fibroblasts and synovial immunity. Curr Opin Pharmacol 2013; 13: 565-9.
25. Laengle UW, Markstein R, Pralet D, Greiner B, Roman D,. Effects of latanoprost and GLC756, a novel dopamine D2 agonist and D1 antagonist, on cultured normal human dermal fibroblasts. Eur J Ophthalmol 2006; 16: 67-72.
26. Partovi M, Sadeghein A, Azizi E, Ostad SN,. Mitogenic effect of L-dopa on human periodontal ligament fibroblast cells. J Endod 2002; 28: 193-6.
27. Wu KY, Hong SJ, Chung YM,. Effects of dopamine antagonists and agonist on cultured human Tenon's fibroblast cells. Kaohsiung J Med Sci 1996; 12: 388-93.
28. Lowin T, Straub RH, Neumann E, Bosserhoff A, Vogel C, Moissl C, et al. Glucocorticoids increase α5 integrin expression and adhesion of synovial fibroblasts but inhibit ERK signaling, migration, and cartilage invasion. Arthritis Rheum 2009; 60: 3623-32.
29. Pfisterer U, Kirkeby A, Torper O, Wood J, Nelander J, Dufour A, et al. Direct conversion of human fibroblasts to dopaminergic neurons. Proc Natl Acad Sci U S A 2011; 108: 10343-8.
30. Caiazzo M, Dell'Anno MT, Dvoretskova E, Lazarevic D, Taverna S, Leo D, et al. Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. Nature 2011; 476: 224-7.
31. Palotas A, Penke B, Palotas M, Kenderessy AS, Kemeny L, Kis E, et al. Haloperidol attenuates β-amyloid-induced calcium imbalance in human fibroblasts. Skin Pharmacol Physiol 2004; 17: 195-9.
32. Murphy EP, McEvoy A, Conneely OM, Bresnihan B, FitzGerald O,. Involvement of the nuclear orphan receptor NURR1 in the regulation of corticotropin-releasing hormone expression and actions in human inflammatory arthritis. Arthritis Rheum 2001; 44: 782-93.
33. Davies MR, Harding CJ, Raines S, Tolley K, Parker AE, Downey-Jones M, et al. Nurr1 dependent regulation of pro-inflammatory mediators in immortalised synovial fibroblasts. J Inflamm (Lond) 2005; 25: 2-15.
34. Zaffaroni M, Marino F, Bombelli R, Rasini E, Monti M, Ferrari M, et al. Therapy with interferon-β modulates endogenous catecholamines in lymphocytes of patients with multiple sclerosis. Exp Neurol 2008; 214: 315-21.
35. high regulatory T lymphocytes in multiple sclerosis patients during interferon-β therapy. Neuroimmunomodulation 2012; 19: 283-92.